Different from other anti-osteoporosis drugs, denosumab (Dmab) is a human monoclonal immunoglobulin G2 (IgG2) antibody that competitively binds to receptor activator of nuclear factor kappa-B ligand (RANKL), preventing the binding of RANKL to its osteoclast-derived receptor (RANK), thereby inhibiting osteoclast-induced bone resorption activity [12]. This evidence concerns the gene TNFSF11 and osteoporosis.